Teva Bicalutamide 50 mg & 150 mg Film-coated tablets
PDF Leaflet Revision Date: 29 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced prostate cancer.
Dosage (summary)
50 mg once daily; 150 mg once daily for two years or until progression.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Coumarin anticoagulants
- Ketoconazole
- Cimetidine
Contraindications
- Hypersensitivity to bicalutamide
- Females
- Children
- Pregnant women
- Nursing mothers
Common side effects
- Anaemia
- Dizziness
- Decreased libido
- Hot flushes
- Hepatotoxicity
Counselling Points
- Take with or without food
- Report any signs of liver dysfunction
- Avoid in pregnancy and breastfeeding
Serious warnings
- Risk of non-alcoholic fatty liver disease
- Monitor hepatic function in severe impairment
Important Disclaimer
The Teva Bicalutamide 50 mg & 150 mg Film-coated tablets professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
